Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Explore content
    • News
      • The week in cell therapy
      • Spotlights
      • In Focus
      • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • eBooks
      • Webinars
      • Podcasts
      • Videos
      • Infographics
      • Partners
      • Events
      • Events news
      • Glossary

    Follow us on social media

  • Our journals
    • Our journals
    • Journal content
    • Journal articles

    Follow us on social media

  • Register
From research to clinical production: scaling iPSC and extracellular vesicle processes 16 days 2 hours 53 mins 29 secs REGISTER NOW

Mastering TIL therapy manufacturing

18 Mar 2024
App Notes & White Papers Cell therapy Manufacturing & scale-up

Gaining ground in cell therapy manufacturing? We’ve been working with leaders in the industry to give you all the tips, insight and guidance you need to become a cell therapy master. Download this eBook and get ahead in no time. 

This content was provided by Cytiva.

Mastering TIL therapy manufacturing-CY39843-24Jan24-EB (F)

 

Top content

  • Cell therapy weekly: investigational AAV-based gene therapy for FSHD completes enrollment
  • Phase I/II Parkinson’s disease cell therapy trial achieves primary endpoint
  • Novel gene therapy harnesses brain’s glymphatic system for targeted delivery

Related tags

cell therapy Cytiva TIL therapy Tumor infiltrating lymphocutes
Previous article

Related articles

1 APR 2021 NEWS
New cell therapy approach shows promise for long-term treatment of Type 1 diabetes mellitus
8 APR 2021 NEWS
Adipose-derived stem cells could help patients with non-healing diabetic foot ulcers
11 MAY 2021 NEWS
Gene therapy approach restores immune function to children with rare immunodeficiency disorder
cell and gene therapy
22 JAN 2021 NEWS
Cell therapy weekly: NICE recommends pioneering CAR-T therapy for patients with lymphoma
10 SEP 2021 THE WEEK IN CELL THERAPY
Cell therapy weekly: US FDA places clinical hold on BMN307 gene therapy study in adults with phenylketonuria
8 MAR 2021 INTERVIEWS
Women to Watch: accelerating the development of MSC products with Dr Suzanne Lipe
  • About
  • Advertising & Sponsorship
  • Expert Panel
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet